Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1988 1
1992 1
1996 1
1999 1
2006 1
2011 2
2012 1
2014 1
2015 1
2016 1
2019 2
2020 1
2021 1
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Uterine corpus epithelioid leiomyosarcoma"
Page 1
Heterologous and rare homologous sarcomas of the uterine corpus: a clinicopathologic review.
Fadare O. Fadare O. Adv Anat Pathol. 2011 Jan;18(1):60-74. doi: 10.1097/PAP.0b013e3182026be7. Adv Anat Pathol. 2011. PMID: 21169739 Review.
Pure sarcomas of the uterine corpus are uncommon, constituting less than 3% of all malignancies at this site, and most of them are leiomyosarcomas and endometrial stromal sarcomas. ...In this article, the clinicopathologic attributes of all earlier reported sarcomas …
Pure sarcomas of the uterine corpus are uncommon, constituting less than 3% of all malignancies at this site, and most of them …
Major clinical research advances in gynecologic cancer in 2015.
Suh DH, Kim M, Kim HJ, Lee KH, Kim JW. Suh DH, et al. J Gynecol Oncol. 2016 Nov;27(6):e53. doi: 10.3802/jgo.2016.27.e53. J Gynecol Oncol. 2016. PMID: 27775259 Free PMC article. Review.
For cervical cancer, update of human papillomavirus vaccines regarding two-dose regimen, 9-valent vaccine, and therapeutic vaccine was reviewed. For corpus cancer, the safety concern of power morcellation in presumed fibroids was explored again with regard to age and preva …
For cervical cancer, update of human papillomavirus vaccines regarding two-dose regimen, 9-valent vaccine, and therapeutic vaccine was revie …
Expanding the Spectrum of NR4A3 Fusion-Positive Gynecologic Leiomyosarcomas.
Momeni-Boroujeni A, Mullaney K, DiNapoli SE, Leitao MM Jr, Hensley ML, Katabi N, Allison DHR, Park KJ, Antonescu CR, Chiang S. Momeni-Boroujeni A, et al. Mod Pathol. 2024 May;37(5):100474. doi: 10.1016/j.modpat.2024.100474. Epub 2024 Mar 18. Mod Pathol. 2024. PMID: 38508521
Recurrent gene fusions have been observed in epithelioid and myxoid variants of uterine leiomyosarcoma. ...Tumors frequently affected premenopausal women, involving the uterine corpus, uterine cervix, or pelvis. All were similarly …
Recurrent gene fusions have been observed in epithelioid and myxoid variants of uterine leiomyosarcoma. ...Tumor …
Major clinical research advances in gynecologic cancer in 2014.
Suh DH, Lee KH, Kim K, Kang S, Kim JW. Suh DH, et al. J Gynecol Oncol. 2015 Apr;26(2):156-67. doi: 10.3802/jgo.2015.26.2.156. J Gynecol Oncol. 2015. PMID: 25872896 Free PMC article. Review.
The HPV test received FDA approval as the primary screening tool of cervical cancer in women aged 25 and older, based on the results of the ATHENA trial, which suggested that the HPV test was a more sensitive and efficient strategy for cervical cancer screening than methods based …
The HPV test received FDA approval as the primary screening tool of cervical cancer in women aged 25 and older, based on the results of the …
CD70 antibody-drug conjugate as a potential therapeutic agent for uterine leiomyosarcoma.
Nakae R, Matsuzaki S, Serada S, Matsuo K, Shiomi M, Sato K, Nagase Y, Matsuzaki S, Nakagawa S, Hiramatsu K, Okazawa A, Kimura T, Egawa-Takata T, Kobayashi E, Ueda Y, Yoshino K, Naka T, Kimura T. Nakae R, et al. Am J Obstet Gynecol. 2021 Feb;224(2):197.e1-197.e23. doi: 10.1016/j.ajog.2020.08.028. Epub 2020 Aug 19. Am J Obstet Gynecol. 2021. PMID: 32822640
BACKGROUND: Uterine leiomyosarcoma is a rare and aggressive gynecologic malignancy originating in the myometrium of the uterine corpus that tends to recur even after complete surgical excision. ...CD70 overexpression was observed in 19 of 21 (90 …
BACKGROUND: Uterine leiomyosarcoma is a rare and aggressive gynecologic malignancy originating in the myometrium of the ute …
Long-term risk of uterine malignancies in women with uterine fibroids confirmed by myomectomy: a population-based study.
Yuk JS, Kim M. Yuk JS, et al. J Obstet Gynaecol. 2022 Oct;42(7):3067-3072. doi: 10.1080/01443615.2022.2091925. Epub 2022 Jul 1. J Obstet Gynaecol. 2022. PMID: 35775461
Epidemiological data on the long-term risk of uterine malignancy with uterine fibroids are lacking. We aimed to determine whether uterine fibroids are a risk factor for uterine cancer. ...Endometrial cancer occurred in 36 44 and 44 36 women in the u …
Epidemiological data on the long-term risk of uterine malignancy with uterine fibroids are lacking. We aimed to determine whet …
Prevalence, characteristics, and risk factors of occult uterine cancer in presumed benign hysterectomy.
Desai VB, Wright JD, Gross CP, Lin H, Boscoe FP, Hutchison LM, Schwartz PE, Xu X. Desai VB, et al. Am J Obstet Gynecol. 2019 Jul;221(1):39.e1-39.e14. doi: 10.1016/j.ajog.2019.02.051. Epub 2019 Mar 7. Am J Obstet Gynecol. 2019. PMID: 30853364 Free PMC article.
We estimated the prevalence of occult uterine cancer (overall and by subtype) and developed and validated risk prediction models using a random split sample approach. ...Prediction models incorporating these risk factors had high negative predictive va …
We estimated the prevalence of occult uterine cancer (overall and by subtype) and developed and validated risk prediction mode …
Different methylation levels in the KLF4, ATF3 and DLEC1 genes in the myometrium and in corpus uteri mesenchymal tumours as assessed by MS-HRM.
Braný D, Dvorská D, Grendár M, Ňachajová M, Szépe P, Lasabová Z, Žúbor P, Višňovský J, Halášová E. Braný D, et al. Pathol Res Pract. 2019 Aug;215(8):152465. doi: 10.1016/j.prp.2019.152465. Epub 2019 May 23. Pathol Res Pract. 2019. PMID: 31176573
Mesenchymal tumours of the corpus uteri comprise common benign lesions - leiomyomas and very rare malignant variants - sarcomas. ...The methylation level was assessed by MS-HRM method and we observed differences in the methylation level between healthy, benign and ( …
Mesenchymal tumours of the corpus uteri comprise common benign lesions - leiomyomas and very rare malignant variants - sarcomas. ...T …
FIGO staging for uterine sarcomas: can the revised 2008 staging system predict survival outcome better?
Yim GW, Nam EJ, Kim SW, Kim YT. Yim GW, et al. Yonsei Med J. 2014 May;55(3):563-9. doi: 10.3349/ymj.2014.55.3.563. Epub 2014 Apr 1. Yonsei Med J. 2014. PMID: 24719120 Free PMC article.
PURPOSE: The aim of this study was to compare survival of patients with uterine sarcomas using the 1988 and 2008 International Federation of Gynecologists and Obstetricians (FIGO) staging systems to determine if revised 2008 staging accurately predicts patient survi …
PURPOSE: The aim of this study was to compare survival of patients with uterine sarcomas using the 1988 and 2008 International Federa …
Patterns of bone morphogenetic protein-2 expression in smooth muscle tumors of the uterine corpus and other uterine tissues.
Fadare O, Renshaw IL, Liang SX. Fadare O, et al. Appl Immunohistochem Mol Morphol. 2011 Jul;19(4):352-9. doi: 10.1097/PAI.0b013e3182013441. Appl Immunohistochem Mol Morphol. 2011. PMID: 21285872
It is concluded that BMP2 is only expressed in a minority of smooth muscle tumors of the uterine corpus, and lacks prognostic significance in leiomyosarcomas. BMP2 is rarely expressed in the other nonendothelial tissues of the human uterine corpus that …
It is concluded that BMP2 is only expressed in a minority of smooth muscle tumors of the uterine corpus, and lacks prognostic …
17 results